432 related articles for article (PubMed ID: 34638293)
21. FGFs/FGFRs-dependent signalling in regulation of steroid hormone receptors - implications for therapy of luminal breast cancer.
Piasecka D; Braun M; Kitowska K; Mieczkowski K; Kordek R; Sadej R; Romanska H
J Exp Clin Cancer Res; 2019 May; 38(1):230. PubMed ID: 31142340
[TBL] [Abstract][Full Text] [Related]
22. A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.
Jerusalem G; Bachelot T; Barrios C; Neven P; Di Leo A; Janni W; de Boer R
Cancer Treat Rev; 2015 Feb; 41(2):94-104. PubMed ID: 25575443
[TBL] [Abstract][Full Text] [Related]
23. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
[TBL] [Abstract][Full Text] [Related]
24. Potential Therapies Targeting the Metabolic Reprogramming of Diabetes-Associated Breast Cancer.
Shum HCE; Wu K; Vadgama J; Wu Y
J Pers Med; 2023 Jan; 13(1):. PubMed ID: 36675817
[TBL] [Abstract][Full Text] [Related]
25. Targeting Key Metabolic Enzymes Involved in Lipid and Protein Biosyntheses for Breast Anticancer Therapies.
Guerram M; Hamdi AM; Zhang LY; Jiang Z
Curr Cancer Drug Targets; 2017; 17(2):158-168. PubMed ID: 27262320
[TBL] [Abstract][Full Text] [Related]
26. Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance.
Brufsky AM; Dickler MN
Oncologist; 2018 May; 23(5):528-539. PubMed ID: 29352052
[TBL] [Abstract][Full Text] [Related]
27. Metabolic reprogramming of T regulatory cells in the hypoxic tumor microenvironment.
Sasidharan Nair V; Saleh R; Toor SM; Cyprian FS; Elkord E
Cancer Immunol Immunother; 2021 Aug; 70(8):2103-2121. PubMed ID: 33532902
[TBL] [Abstract][Full Text] [Related]
28. Long Non-coding RNAs Involved in Metabolic Alterations in Breast and Prostate Cancers.
Kamada S; Takeiwa T; Ikeda K; Horie-Inoue K; Inoue S
Front Oncol; 2020; 10():593200. PubMed ID: 33123488
[TBL] [Abstract][Full Text] [Related]
29. Nuclear accumulation of MKL1 in luminal breast cancer cells impairs genomic activity of ERα and is associated with endocrine resistance.
Jehanno C; Fernandez-Calero T; Habauzit D; Avner S; Percevault F; Jullion E; Le Goff P; Coissieux MM; Muenst S; Marin M; Michel D; Métivier R; Flouriot G
Biochim Biophys Acta Gene Regul Mech; 2020 May; 1863(5):194507. PubMed ID: 32113984
[TBL] [Abstract][Full Text] [Related]
30. Molecular Changes During Breast Cancer and Mechanisms of Endocrine Therapy Resistance.
Radhi S
Prog Mol Biol Transl Sci; 2016; 144():539-562. PubMed ID: 27865467
[TBL] [Abstract][Full Text] [Related]
31. Cancer Stem Cell-Associated Pathways in the Metabolic Reprogramming of Breast Cancer.
El-Sahli S; Wang L
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33266219
[TBL] [Abstract][Full Text] [Related]
32. Metabolic reprogramming of the tumor microenvironment by p62 and its partners.
Reina-Campos M; Shelton PM; Diaz-Meco MT; Moscat J
Biochim Biophys Acta Rev Cancer; 2018 Aug; 1870(1):88-95. PubMed ID: 29702207
[TBL] [Abstract][Full Text] [Related]
33. Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications.
Montemurro F; Di Cosimo S; Arpino G
Ann Oncol; 2013 Nov; 24(11):2715-24. PubMed ID: 23908178
[TBL] [Abstract][Full Text] [Related]
34. Current status of hormone therapy in patients with hormone receptor positive (HR+) advanced breast cancer.
Dalmau E; Armengol-Alonso A; Muñoz M; Seguí-Palmer MÁ
Breast; 2014 Dec; 23(6):710-20. PubMed ID: 25311296
[TBL] [Abstract][Full Text] [Related]
35. Pleiotropic Mechanisms Drive Endocrine Resistance in the Three-Dimensional Bone Microenvironment.
Dhimolea E; de Matos Simoes R; Kansara D; Weng X; Sharma S; Awate P; Liu Z; Gao D; Mitsiades N; Schwab JH; Chen Y; Jeselsohn R; Culhane AC; Brown M; Georgakoudi I; Mitsiades CS
Cancer Res; 2021 Jan; 81(2):371-383. PubMed ID: 32859606
[TBL] [Abstract][Full Text] [Related]
36. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
37. Insights into biology of luminal HER2 vs. enriched HER2 subtypes: Therapeutic implications.
Harbeck N
Breast; 2015 Nov; 24 Suppl 2():S44-8. PubMed ID: 26321480
[TBL] [Abstract][Full Text] [Related]
38. Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer.
Zhang H; Stephens LC; Kumar R
Clin Cancer Res; 2006 Mar; 12(5):1479-86. PubMed ID: 16533771
[TBL] [Abstract][Full Text] [Related]
39. Recent advances in the role of AMP-activated protein kinase in metabolic reprogramming of metastatic cancer cells: targeting cellular bioenergetics and biosynthetic pathways for anti-tumor treatment.
Tyszka-Czochara M; Konieczny P; Majka M
J Physiol Pharmacol; 2018 Jun; 69(3):. PubMed ID: 30279304
[TBL] [Abstract][Full Text] [Related]
40. Metabolic Reprogramming of Colorectal Cancer Cells and the Microenvironment: Implication for Therapy.
Nenkov M; Ma Y; Gaßler N; Chen Y
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34200820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
